FDA Grants Priority Review to ARV-1801, Potential Antibiotic for Pulmonary Flares in CF
Arrevus announced the Qualified Infectious Disease Product (QIDP) award given to oral ARV-1801,and plans to open a Phase 2 trial in CF patients.
0 Comments